Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 2
1981 4
1982 2
1984 4
1985 1
1987 1
1988 4
1991 2
1993 2
1996 2
1997 2
1998 1
1999 3
2000 4
2002 1
2003 6
2004 5
2005 8
2006 4
2007 5
2008 7
2009 6
2010 13
2011 8
2012 7
2013 6
2014 12
2015 12
2016 8
2017 11
2018 1
2019 7
2020 9
2021 13
2022 16
2023 12
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Al-Batran SE, et al. Among authors: pink d. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982686 Clinical Trial.
Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles.
Brown DW, Wee P, Bhandari P, Bukhari A, Grin L, Vega H, Hejazi M, Sosnowski D, Ablack J, Clancy EK, Pink D, Kumar J, Solis Ares MP, Lamb S, Quevedo R, Rawal B, Elian F, Rana N, Morales L, Govindasamy N, Todd B, Delmage A, Gupta S, McMullen N, MacKenzie D, Beatty PH, Garcia H, Parmar M, Gyoba J, McAllister C, Scholz M, Duncan R, Raturi A, Lewis JD. Brown DW, et al. Among authors: pink d. Cell. 2024 Sep 19;187(19):5357-5375.e24. doi: 10.1016/j.cell.2024.07.023. Epub 2024 Sep 10. Cell. 2024. PMID: 39260374 Free article.
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P. Joensuu H, et al. Among authors: pink d. JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347. JAMA. 2012. PMID: 22453568 Clinical Trial.
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M. Stein A, et al. Among authors: pink d. JAMA Oncol. 2022 Aug 1;8(8):1150-1158. doi: 10.1001/jamaoncol.2022.2228. JAMA Oncol. 2022. PMID: 35737383 Free PMC article. Clinical Trial.
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review.
Veltsista PD, Oberacker E, Ademaj A, Corradini S, Eckert F, Flörcken A, Kaul D, Lindner LH, Issels R, Ott OJ, Pink D, Potkrajcic V, Reichardt P, Roohani S, Spalek MJ, Riesterer O, Zips D, Ghadjar P. Veltsista PD, et al. Among authors: pink d. Int J Hyperthermia. 2023;40(1):2236337. doi: 10.1080/02656736.2023.2236337. Int J Hyperthermia. 2023. PMID: 37468132 Free article. Review.
Human pathogens and the phyllosphere.
Whipps JM, Hand P, Pink DA, Bending GD. Whipps JM, et al. Among authors: pink da. Adv Appl Microbiol. 2008;64:183-221. doi: 10.1016/S0065-2164(08)00407-3. Adv Appl Microbiol. 2008. PMID: 18485286 Review. No abstract available.
Extravasations of oxaliplatin.
Kretzschmar A, Pink D, Thuss-Patience P, Dörken B, Reichert P, Eckert R. Kretzschmar A, et al. Among authors: pink d. J Clin Oncol. 2003 Nov 1;21(21):4068-9. doi: 10.1200/JCO.2003.99.095. J Clin Oncol. 2003. PMID: 14581435 No abstract available.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M, Al-Batran SE, Goetze TO, Thuss-Patience P, Knorrenschild JR, Goekkurt E, Folprecht G, Ettrich TJ, Lindig U, Luley KB, Pink D, Dechow T, Sookthai D, Junge S, Loose M, Pauligk C, Lorenzen S. Masetti M, et al. Among authors: pink d. Int J Cancer. 2024 Jun 15;154(12):2142-2150. doi: 10.1002/ijc.34894. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447003 Clinical Trial.
[Systemic therapy of soft tissue sarcomas].
Pink D, Bertz-Lepel J, Reichardt P. Pink D, et al. Pathologe. 2011 Feb;32(1):65-71. doi: 10.1007/s00292-010-1397-8. Pathologe. 2011. PMID: 21053001 Review. German.
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Vogel A, Saborowski A, Wenzel P, Wege H, Folprecht G, Kretzschmar A, Schütt P, Jacobasch L, Ziegenhagen N, Boeck S, Zhang D, Kanzler S, Belle S, Mohm J, Gökkurt E, Lerchenmüller C, Graeven U, Pink D, Götze T, Kirstein MM. Vogel A, et al. Among authors: pink d. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):734-744. doi: 10.1016/S2468-1253(24)00119-5. Epub 2024 Jun 10. Lancet Gastroenterol Hepatol. 2024. PMID: 38870977 Free article. Clinical Trial.
204 results